King Faisal Specialist Hospital, Riyadh – United Arab Emirates
About Dr. Fahad Almohareb
Dr. Fahad Almohareb is a Senior Consultant in Adult Haematology with specialist expertise in haematopoietic stem cell transplantation, adult haemoglobin disorders (sickle cell disease, thalassaemia), and Philadelphia-positive acute leukaemia — a senior haematology specialist in Riyadh, Saudi Arabia with decades of clinical and academic experience supporting international patients. He is co-author of a landmark 1984–2016 Saudi HSCT paper covering 6,184 transplants and serves on the Editorial Board of a leading hematology, oncology and stem cell therapy journal.
- Senior Consultant Haematologist specialising in HSCT and adult haemoglobin disorders
- Co-author of a landmark 1984–2016 Saudi HSCT paper covering 6,184 transplants
- Editorial Board member for a leading hematology, oncology and stem cell therapy journal
- Co-investigator on an international learning collaborative for haploidentical BMT in sickle cell disease
- Contributing author on Philadelphia-positive B-ALL transplant outcomes research
Qualifications & Credentials
Medical Degrees
- MBBS — Bachelor of Medicine and Bachelor of Surgery
- Internal Medicine Residency
Fellowships & Special Training
- Fellowship in Adult Haematology
- Fellowship in Haematopoietic Stem Cell Transplantation and Cellular Therapy
- Advanced Training in Haemoglobin Disorders and Transplantation
Certifications & Accreditations
- Saudi Commission for Health Specialties (SCFHS) — Registered Senior Consultant
- American Society of Hematology (ASH) — Member
- European Society for Blood and Marrow Transplantation (EBMT) — Member
Areas of Expertise
Major Conditions Treated
- Sickle Cell Disease (Adult)
- Beta-Thalassaemia (Adult)
- Acute Lymphoblastic Leukaemia (Including Ph+)
- Acute Myeloid Leukaemia
- Myelodysplastic Syndrome (MDS)
- Aplastic Anaemia
- Graft-versus-Host Disease
- Multiple Myeloma (Transplant Candidates)
- Myeloproliferative Neoplasms
Sub-specialties
- Adult Haematopoietic Stem Cell Transplantation: Matched-related, matched-unrelated, and haploidentical HSCT for adult haematological malignancies and haemoglobin disorders — a senior stem cell transplant specialist in Riyadh for international patients.
- Adult Haemoglobin Disorders: Curative and supportive care for adult sickle cell disease and thalassaemia, including HSCT candidacy evaluation and post-transplant management.
- Philadelphia-Positive Acute Leukaemia: Integrated TKI (imatinib, dasatinib, ponatinib) therapy with chemotherapy and HSCT for Ph+ B-ALL.
Advanced Procedures & Treatments
- Matched-Related and Matched-Unrelated HSCT
- Haploidentical Stem Cell Transplantation
- HSCT for Adult Sickle Cell Disease and Thalassaemia
- Ph+ B-ALL TKI-Combined Protocols
- Post-Transplant Cyclophosphamide
- Chronic GVHD Management
- MRD Monitoring and Pre-Emptive Therapy
- Gene Therapy Coordination for Haemoglobinopathies
Professional Experience
Current Affiliation
- Senior Consultant, Adult Haematology HSCT Section — King Faisal Specialist Hospital & Research Centre (KFSHRC), Riyadh, Saudi Arabia (Present)
Past Affiliations
- Fellowship training in Adult Haematology and HSCT — completed prior to KFSHRC consultancy
Academic & Research Roles
- Editorial Board — Hematology/Oncology and Stem Cell Therapy (HOSCT)
- Co-investigator — International Learning Collaborative on Haploidentical BMT for Sickle Cell Disease
- Faculty — KFSHRC adult haematology and HSCT training programmes
Key Achievements
- Co-author of landmark 1984–2016 Saudi HSCT paper covering 6,184 transplants across four centres
- Co-investigator on an international learning collaborative on haplo-BMT for SCD
- Contributing author on BJH 2026 Philadelphia-positive B-ALL transplant outcomes
- Decades of clinical experience in adult HSCT and haemoglobin disorders
Awards & Recognitions
National & International Awards
- Information not publicly available.
Professional Memberships
- American Society of Hematology (ASH)
- European Society for Blood and Marrow Transplantation (EBMT)
- Saudi Society of Haematology
- Editorial Board — Hematology/Oncology and Stem Cell Therapy
Research & Publications
Published Papers (Selected)
- Almohareb F, et al. Haematopoietic Stem Cell Transplantation in Saudi Arabia — 6,184 Transplants from 1984–2016. Hematol Oncol Stem Cell Ther. 2021;14:169-178. PubMed 32888899.
- Kassim AA, Almohareb FI, et al. International Learning Collaborative on Haploidentical BMT for Sickle Cell Disease. Blood. 2024;143:2654-2665.
- Almohareb FI, et al. Philadelphia-Positive B-Cell Acute Lymphoblastic Leukaemia — Transplant Outcomes. British Journal of Haematology. 2026.
Ongoing Research & Clinical Interests
- Long-term outcomes of HSCT in adult sickle cell disease and thalassaemia
- Haploidentical BMT optimisation
- Philadelphia-positive acute lymphoblastic leukaemia transplantation
- Regional collaborative research on HSCT
Estimated Treatment Costs
| Procedure / Consultation | Estimated Cost (INR) | Estimated Cost (USD) |
|---|---|---|
| Haematology Consultation | ₹1,000 – ₹2,500 | $12 – $30 |
| Bone Marrow Biopsy & Aspirate | ₹8,000 – ₹25,000 | $100 – $300 |
| Chemotherapy (per cycle) | ₹40,000 – ₹2,00,000 | $480 – $2,400 |
| Autologous Stem Cell Transplant | ₹12,00,000 – ₹18,00,000 | $14,500 – $21,700 |
| Allogeneic Stem Cell Transplant | ₹18,00,000 – ₹30,00,000 | $21,700 – $36,100 |
| CAR-T Cell Therapy | ₹1,50,00,000 – ₹4,00,00,000 | $180,000 – $480,000 |
*Indicative estimates only. Actual costs subject to hospital pricing, case complexity, and insurance. Contact Cancer Rounds for a personalised quote.
Frequently Asked Questions
1. What advanced technologies does Dr. Fahad Almohareb use in Adult Haematology — Stem Cell Transplantation & Haemoglobin Disorders treatment?
Dr. Fahad Almohareb uses advanced adult haematology and transplant technologies including matched-related, matched-unrelated, and haploidentical stem cell transplantation, post-transplant cyclophosphamide protocols, HSCT for adult sickle cell disease and thalassaemia, Philadelphia-positive B-ALL TKI-combined protocols (imatinib, dasatinib, ponatinib), reduced-intensity conditioning regimens, and minimal residual disease (MRD) monitoring. Virtual consultations and remote second opinions are also available to international patients through Cancer Rounds.
2. What conditions does Dr. Fahad Almohareb specialize in treating?
Dr. Fahad Almohareb specialises in Adult Haematology, Stem Cell Transplantation, and Haemoglobin Disorders, treating adult sickle cell disease, beta-thalassaemia, acute lymphoblastic leukaemia (including Philadelphia-positive), acute myeloid leukaemia, myelodysplastic syndrome, aplastic anaemia, graft-versus-host disease, multiple myeloma (transplant candidates), and myeloproliferative neoplasms. International patients seeking the best adult haematology and BMT doctor in India or Saudi Arabia benefit from his decades of experience.
3. How do I book an appointment with Dr. Fahad Almohareb?
Appointments with Dr. Fahad Almohareb can be booked directly through the Cancer Rounds website or by contacting their international patient department for priority scheduling.
4. Can international patients receive treatment from Dr. Fahad Almohareb?
Yes. Cancer Rounds provides full assistance for international patients seeking treatment from Dr. Fahad Almohareb, including medical visa invitation letters, airport transfers, and local accommodation coordination.
5. What support is available for international patients?
International patients benefit from a dedicated concierge service provided by Cancer Rounds, including language interpretation, financial counselling, and pre-travel virtual consultations to review medical records before arrival.
6. Does Dr. Fahad Almohareb offer second opinions for Adult Haematology — Stem Cell Transplantation & Haemoglobin Disorders cases?
Yes. Second opinion consultations for Adult Haematology, HSCT, and haemoglobin disorder cases can be arranged via Cancer Rounds, enabling international patients to review transplant eligibility, conditioning regimens, and curative therapy options with Dr. Fahad Almohareb.
